Payment overview · 2025
General Payments
$219.00
11 reported records · 8 companies
Healthcare provider profile · identity verified
Lance C Robinson, MD
Allopathic & Osteopathic Physicians|Family Medicine · CLIFTON, TX · NPI 1437686474
Verified facts
What the public records show
CMS Open Payments records show Lance C Robinson, MD received $219.00 in general payments during 2025 across 11 reported records.
Biogen, Inc. accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biogen, Inc. | Unresolved — no canonical attribution shown | $55.42 | 25.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.43 | 23.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.36 | 11.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.16 | 11.0% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $17.30 | 7.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.78 | 7.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.86 | 7.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.69 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $219.00 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $55.42 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 388 | 96 |
| Losartan Potassium | Losartan Potassium | 281 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 269 | 69 |
| Gabapentin | Gabapentin | 250 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 232 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 56 |
| Lisinopril | Lisinopril | 208 | 58 |
| Furosemide | Furosemide | 197 | 41 |
| Montelukast Sodium | Montelukast Sodium | 179 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 57 |
| Tramadol Hcl | Tramadol Hcl | 165 | 41 |
| Potassium Chloride | Potassium Chloride | 155 | 36 |
| Metformin Hcl | Metformin Hcl | 142 | 34 |
| Omeprazole | Omeprazole | 135 | 42 |
| Ozempic | Semaglutide | 135 | 19 |
| Trazodone Hcl | Trazodone Hcl | 135 | 30 |
| Eliquis | Apixaban | 134 | 23 |
| Carvedilol | Carvedilol | 131 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 35 |
| Donepezil Hcl | Donepezil Hcl | 108 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 106 | 92 |
| Simvastatin | Simvastatin | 106 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 20 |
| Jardiance | Empagliflozin | 94 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 32 |
| Sertraline Hcl | Sertraline Hcl | 86 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 33 |
| Levetiracetam | Levetiracetam | 85 | suppressed |
| Alprazolam | Alprazolam | 80 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 14 |
| Ezetimibe | Ezetimibe | 73 | 18 |
| Spironolactone | Spironolactone | 72 | 18 |
| Mounjaro | Tirzepatide | 70 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 20 |
| Famotidine | Famotidine | 63 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 15 |
| Pregabalin | Pregabalin | 58 | 14 |
| Alendronate Sodium | Alendronate Sodium | 57 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 11 |
| Finasteride | Finasteride | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Prednisone | Prednisone | 50 | 38 |
| Celecoxib | Celecoxib | 49 | 16 |
| Metformin Hcl Er | Metformin Hcl | 49 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Cephalexin | Cephalexin | 44 | 23 |
| Glimepiride | Glimepiride | 44 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 35 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | 11 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Cefdinir | Cefdinir | 36 | 31 |
| Baclofen | Baclofen | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 19 |
| Prazosin Hcl | Prazosin Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Lacosamide | Lacosamide | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Estradiol | Estradiol | 26 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 16 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 16 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Azithromycin | Azithromycin | 20 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Naproxen | Naproxen | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Unifine Pentips Plus | Pen Needle, Diabetic | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $219.00 · 11 records | Biogen, Inc. | Auvelity, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, Exparel, GARDASIL 9, JARDIANCE, NURTEC ODT, PROQUAD, ZEPBOUND, ZURZUVAE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error